ArticleScientific reports2026
Comparative analysis of extracellular vesicles released from resting neutrophils under distinct pharmacological inhibition.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cells in resting conditions spontaneously release extracellular vesicles (EVs). Comparative studies for pharmacological EV inhibition, targeting multiple biogenesis elements within the same cell type, remain scarce. Spontaneously released neutrophil-derived EVs are important mediators of immunity that exhibit anti-inflammatory properties. Here, we present a systematic investigation of seven pharmacologic inhibitors (calpeptin, D-pantethine, Y27632, cytochalasin D, GW4869, R5421, and Nexinhib20) on the quantitative and qualitative properties of the selected EV population (16,100 g pellet obtained by filtration, size‑exclusion chromatography, and differential centrifugation) derived from resting neutrophils. We measured EV numbers, size distribution, total lipid, protein, and RNA content. We also analyzed EV morphology by cryogenic electron microscopy and EV cargo composition qualitatively by mass spectrometry and RNA sequencing. The results revealed differential profiles of proteins, mRNAs, and miRNAs depending on the inhibitor applied, as well as changes in the physical characteristics of the EVs. Inhibition of a single biogenesis pathway often led to compensatory upregulation of alternative vesicle formation mechanisms, as reflected in preserved EV numbers but altered cargo composition. These findings underscore the necessity of carefully selecting and reporting EV-inhibiting pharmacologic agents, as each compound uniquely shapes both the quantity and biological cargo of released EVs, and may have physiological consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.